← 產業報告目錄
Liver Disease Management Market Size, Share & Trends Analysis Report By Diagnosis (Endoscopy, Imaging, Biopsy, Others), By Treatment (Anti-Viral Drugs, Targeted Therapy, Chemotherapy, Others), By End-Use, By Region, And by Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-21頁數 178報告編號 INSIGHTACE-89f3654507
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The Liver Disease Management Market on a global scale was estimated at USD 26.78 Billion in 2024 and is forecasted to attain USD 52.28 Billion by 2034, with a projected CAGR of 7.1% between 2025 and 2034.
Liver Disease Management covers key industry insights & findings from the report:
The advent of the frequency of lifestyle-related liver diseases which are influenced by factors such as a sedentary lifestyle, poor diet, and alcohol. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
The market's upward path is propelled by surging healthcare spending, technological evolution, and the surging focus on personalized and precision-based approaches in healthcare.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, propelled by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Liver Disease Management Market Snapshot
Chapter 4. Global Liver Disease Management Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Diagnosis Estimates & Trend Analysis
5.1. by Diagnosis & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Diagnosis:
5.2.1. Endoscopy
5.2.2. Imaging
5.2.3. Biopsy
5.2.4. Others
Chapter 6. Market Segmentation 2: by Treatment Estimates & Trend Analysis
6.1. by Treatment & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Treatment:
6.2.1. Anti-Viral Drugs
6.2.2. Targeted Therapy
6.2.3. Chemotherapy
6.2.4. Others
Chapter 7. Market Segmentation 3: by End-Use Estimates & Trend Analysis
7.1. by End-Use & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-Use:
7.2.1. Clinics
7.2.2. Hospitals
7.2.3. Diagnostics Laboratories
7.2.4. Others
Chapter 8. Liver Disease Management Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Liver Disease Management Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2021-2034
8.1.2. North America Liver Disease Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2021-2034
8.1.3. North America Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.1.4. North America Liver Disease Management Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.2.2. Europe Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.2.3. Europe Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.2.4. Europe Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.3.2. Asia Pacific Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.3.3. Asia-Pacific Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.3.4. Asia Pacific Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.4.2. Latin America Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.4.3. Latin America Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.4.4. Latin America Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.5.2. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.5.3. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.5.4. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Abbott
9.2.2. AbbVie Inc.
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.4. Bristol-Myers Squibb Company
9.2.5. Astellas Pharma Inc.
9.2.6. Lilly
9.2.7. Merck & Co., Inc.
9.2.8. Pfizer Inc.
9.2.9. Novartis AG
9.2.10. Johnson & Johnson Private Limited
9.2.11. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們